Literature DB >> 18849396

Determinants of right ventricular ejection fraction in pulmonary arterial hypertension.

Steven M Kawut1, Nadine Al-Naamani2, Cara Agerstrand2, Erika Berman Rosenzweig3, Cherise Rowan3, Robyn J Barst3, Steven Bergmann4, Evelyn M Horn2.   

Abstract

BACKGROUND: Right ventricular function is a key determinant of exercise capacity and survival in pulmonary arterial hypertension (PAH). We aimed to study the predictors of right ventricular ejection fraction (RVEF) in patients with newly diagnosed PAH.
METHODS: We performed a cross-sectional analysis of a retrospective cohort of consecutive patients with idiopathic, familial, or anorexigen-associated PAH who underwent equilibrium radionuclide angiography for measurement of RVEF at baseline.
RESULTS: Of the 84 patients in the cohort, 63 underwent equilibrium radionuclide angiography and right heart catheterization and were included. The mean age was 41 +/- 13 years, and 79% of the patients were female. The mean RVEF was 30 +/- 8%. RVEF was directly associated with right ventricular stroke volume index and cardiac index, and inversely associated with pulmonary vascular resistance index from right heart catheterization (all p < 0.001). Older age and male sex were associated with lower RVEF (p < 0.05) after adjustment for pulmonary vascular resistance index and left ventricular ejection fraction. Higher plasma von Willebrand factor levels were also independently associated with lower RVEF (p = 0.01) (n = 55). Body size and type of PAH were not associated with RVEF.
CONCLUSIONS: Older patients and males with PAH had lower RVEF at baseline than younger patients and females, even after controlling for left ventricular function and hemodynamics. Higher plasma von Willebrand factor levels, a marker of endothelial dysfunction, were also associated with lower RVEF.

Entities:  

Mesh:

Year:  2008        PMID: 18849396      PMCID: PMC2834785          DOI: 10.1378/chest.08-1758

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  42 in total

1.  Clinical differences between idiopathic and scleroderma-related pulmonary hypertension.

Authors:  Micah R Fisher; Stephen C Mathai; Hunter C Champion; Reda E Girgis; Traci Housten-Harris; Laura Hummers; Jerry A Krishnan; Fredrick Wigley; Paul M Hassoun
Journal:  Arthritis Rheum       Date:  2006-09

2.  Prognostic value of right ventricular mass, volume, and function in idiopathic pulmonary arterial hypertension.

Authors:  Serge A van Wolferen; Johannes T Marcus; Anco Boonstra; Koen M J Marques; Jean G F Bronzwaer; Marieke D Spreeuwenberg; Pieter E Postmus; Anton Vonk-Noordegraaf
Journal:  Eur Heart J       Date:  2007-01-22       Impact factor: 29.983

3.  Adaptation of the right ventricle to an increased afterload in the chronically volume overloaded heart.

Authors:  Gábor Szabó; Pál Soós; Susanne Bährle; Tamás Radovits; Ernst Weigang; Violetta Kékesi; Béla Merkely; Siegfried Hagl
Journal:  Ann Thorac Surg       Date:  2006-09       Impact factor: 4.330

Review 4.  The effects of biological sex and diet on the development of heart failure.

Authors:  John P Konhilas; Leslie A Leinwand
Journal:  Circulation       Date:  2007-12-04       Impact factor: 29.690

5.  Right coronary artery flow impairment in patients with pulmonary hypertension.

Authors:  Serge A van Wolferen; J Tim Marcus; Nico Westerhof; Marieke D Spreeuwenberg; Koen M J Marques; Jean G F Bronzwaer; Ivo R Henkens; C Tji-Joong Gan; Anco Boonstra; Pieter E Postmus; Anton Vonk-Noordegraaf
Journal:  Eur Heart J       Date:  2007-12-08       Impact factor: 29.983

6.  Unveiling gender differences in demand ischemia: a study in a rat model of genetic hypertension.

Authors:  Bruno K Podesser; Mohit Jain; Soeun Ngoy; Carl S Apstein; Franz R Eberli
Journal:  Eur J Cardiothorac Surg       Date:  2006-12-18       Impact factor: 4.191

7.  A USA-based registry for pulmonary arterial hypertension: 1982-2006.

Authors:  T Thenappan; S J Shah; S Rich; M Gomberg-Maitland
Journal:  Eur Respir J       Date:  2007-09-05       Impact factor: 16.671

8.  Extent of MRI delayed enhancement of myocardial mass is related to right ventricular dysfunction in pulmonary artery hypertension.

Authors:  Gerry P McCann; C T Gan; Aernout M Beek; Hans W M Niessen; Anton Vonk Noordegraaf; Albert C van Rossum
Journal:  AJR Am J Roentgenol       Date:  2007-02       Impact factor: 3.959

9.  Normal reference values for the adult right ventricle by magnetic resonance imaging.

Authors:  Harikrishna Tandri; Samantapudi K Daya; Khurram Nasir; Chandra Bomma; João A C Lima; Hugh Calkins; David A Bluemke
Journal:  Am J Cardiol       Date:  2006-10-27       Impact factor: 2.778

10.  Relation of sex to morbidity and mortality in patients with heart failure and reduced or preserved left ventricular ejection fraction.

Authors:  François Alla; Ahmad Y Al-Hindi; Craig R Lee; Todd A Schwartz; J Herbert Patterson; Kirkwood F Adams
Journal:  Am Heart J       Date:  2007-06       Impact factor: 4.749

View more
  52 in total

Review 1.  Strategic plan for lung vascular research: An NHLBI-ORDR Workshop Report.

Authors:  Serpil Erzurum; Sharon I Rounds; Troy Stevens; Micheala Aldred; Jason Aliotta; Stephen L Archer; Kewal Asosingh; Robert Balaban; Natalie Bauer; Jahar Bhattacharya; Harm Bogaard; Gaurav Choudhary; Gerald W Dorn; Raed Dweik; Karen Fagan; Michael Fallon; Toren Finkel; Mark Geraci; Mark T Gladwin; Paul M Hassoun; Marc Humbert; Naftali Kaminski; Steven M Kawut; Joseph Loscalzo; Donald McDonald; Ivan F McMurtry; John Newman; Mark Nicolls; Marlene Rabinovitch; Judy Shizuru; Masahiko Oka; Peter Polgar; David Rodman; Paul Schumacker; Kurt Stenmark; Rubin Tuder; Norbert Voelkel; Eugene Sullivan; Richard Weinshilboum; Mervin C Yoder; Yingming Zhao; Dorothy Gail; Timothy M Moore
Journal:  Am J Respir Crit Care Med       Date:  2010-09-10       Impact factor: 21.405

2.  Hemodynamic predictors of survival in scleroderma-related pulmonary arterial hypertension.

Authors:  Aránzazu Campo; Stephen C Mathai; Jérôme Le Pavec; Ari L Zaiman; Laura K Hummers; Danielle Boyce; Traci Housten; Hunter C Champion; Noah Lechtzin; Fredrick M Wigley; Reda E Girgis; Paul M Hassoun
Journal:  Am J Respir Crit Care Med       Date:  2010-03-25       Impact factor: 21.405

Review 3.  Pulmonary hypertension in women.

Authors:  Meredith E Pugh; Anna R Hemnes
Journal:  Expert Rev Cardiovasc Ther       Date:  2010-11

Review 4.  New and Emerging Therapies for Pulmonary Arterial Hypertension.

Authors:  Edda Spiekerkoetter; Steven M Kawut; Vinicio A de Jesus Perez
Journal:  Annu Rev Med       Date:  2018-09-14       Impact factor: 13.739

Review 5.  Pulmonary arterial hypertension: a comparison between children and adults.

Authors:  R J Barst; S I Ertel; M Beghetti; D D Ivy
Journal:  Eur Respir J       Date:  2011-03       Impact factor: 16.671

6.  What does the time constant of the pulmonary circulation tell us about the progression of right ventricular dysfunction in pulmonary arterial hypertension?

Authors:  A Bellofiore; Z Wang; N C Chesler
Journal:  Pulm Circ       Date:  2015-06       Impact factor: 3.017

7.  Inhibiting oestrogen signalling in pulmonary arterial hypertension: sex, drugs and research.

Authors:  Tim Lahm; Steven M Kawut
Journal:  Eur Respir J       Date:  2017-08-03       Impact factor: 16.671

Review 8.  Sex, Gender, and Sex Hormones in Pulmonary Hypertension and Right Ventricular Failure.

Authors:  James Hester; Corey Ventetuolo; Tim Lahm
Journal:  Compr Physiol       Date:  2019-12-18       Impact factor: 9.090

9.  Race and sex differences in response to endothelin receptor antagonists for pulmonary arterial hypertension.

Authors:  Nicole B Gabler; Benjamin French; Brian L Strom; Ziyue Liu; Harold I Palevsky; Darren B Taichman; Steven M Kawut; Scott D Halpern
Journal:  Chest       Date:  2011-09-22       Impact factor: 9.410

Review 10.  Pharmacology of Pulmonary Arterial Hypertension: An Overview of Current and Emerging Therapies.

Authors:  Monika Spaczyńska; Susana F Rocha; Eduardo Oliver
Journal:  ACS Pharmacol Transl Sci       Date:  2020-07-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.